Synthalis

The project represents a legitimate early-stage biotech startup (Synthalis) with a website and stated mission in AI drug discovery. However, the submission contains severe credibility issues, specifically the patently false claim that 'most people have used my product' (despite the company being in pre-clinical development) and the misuse of financial terminology ('marketcap: 500000'). While the sector is high-impact, the lack of verifiable traction, technical detail, or functional product places it in the 'minimal traction' category, saved only by the inherent potential of the pharmaceutical domain.